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Abstract 
PBX1 is an essential developmental transcription factor, mutations in which have recently been 
associated with CAKUTHED syndrome, characterised by multiple congenital defects including 
congenital heart disease. During analysis of a whole-exome-sequenced cohort of heterogeneous CHD 
patients, we identified a de novo missense variant, PBX1:c.551G>C p.R184P, in a patient with 
tetralogy of Fallot with absent pulmonary valve and extra-cardiac phenotypes. Functional analysis of 
this variant by creating a CRISPR-Cas9 gene-edited mouse model revealed multiple congenital 
anomalies. Congenital heart defects (persistent truncus arteriosus and ventricular septal defect), 
hypoplastic lungs, hypoplastic/ectopic kidneys, aplastic adrenal glands and spleen, as well as atretic 
trachea and palate defects were observed in the homozygous mutant embryos at multiple stages of 
development. We also observed developmental anomalies in a proportion of heterozygous embryos, 
suggestive of a dominant mode of inheritance. Analysis of gene expression and protein levels revealed 
that although Pbx1 transcripts are higher in homozygotes, amounts of PBX1 protein are significantly 
decreased. Here, we have presented the first functional model of a missense PBX1 variant and provide 
strong evidence that p.R184P is disease-causal. Our findings also expand the phenotypic spectrum 
associated with pathogenic PBX1 variants in both humans and mice.  
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Introduction 
Congenital heart disease (CHD) affects approximately 1 in a 100 live births (1). These structural 
malformations of the heart that can affect the ventricles, atria, valves or the great vessels, can vary in 
severity, and require variable degrees of intervention. They may occur in isolation or as part of a 
broader syndrome comprising multiple extra-cardiac phenotypes. Sporadic incidence of CHD, in 
families with no history of heart defects, is higher than familial cases of CHD (2). Evidence that there 
is a genetic basis to CHD has been growing over decades of research, however currently a clinically 
actionable genetic diagnosis is achieved for only 30% of cases (3). The clinical utility of a genetic 
diagnosis is highlighted by the vital role it plays in management of the patient's phenotypic diagnosis 
and prognosis in cases of syndromic CHD (4), as well as calculating the recurrence risk. Currently, 
the number of genes implicated in CHD causality remains limited. Genes with the strongest support 
for causality are those that are recurrently mutated in CHD patients with robust functional evidence 
indicative of pathogenicity. The utilisation of massively parallel sequencing techniques such as whole 
exome sequencing and whole genome sequencing has provided an opportunity for novel CHD gene 
discovery in an unbiased manner. Recent studies have put forward many genes with variants 
identified in CHD patients that have predicted-pathogenicity in silico but so far have not been verified 
functionally (3, 5, 6).  
We recently analysed variants identified in a cohort of CHD patients who underwent whole exome 
sequencing (WES) (5). A variant of uncertain significance, PBX1:c.551G>C p.R184P, was identified 
in pre-B cell leukemia factor 1 (PBX1) in a patient with tetralogy of Fallot (TOF) and extra-cardiac 
phenotypes. PBX1 belongs to the TALE class of transcription factors of which there are 3 others 
(PBX2, PBX3, and PBX4). All four proteins share strong sequence homology within three main 
protein domains: PBC-A, PBC-B, and the C-terminal homeodomain (7, 8). They are highly expressed 
during embryonic development with Pbx1, Pbx2, and Pbx3 strongly expressed in the heart (9, 10). 
Recently, pathogenic variants in PBX1 were implicated in the causality of a novel 
syndrome, congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, 
abnormal ears, or developmental delay (CAKUTHED, OMIM:617641). This syndrome has high 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz231/5585438 by U
niversity of C
alifornia, San Francisco user on 13 N
ovem
ber 2019
4 
 
phenotypic variability, however is generally characterised by congenital anomalies of the urogenital 
system, craniofacial anomalies, and developmental delay (11-15). Congenital heart defects have also 
been observed in some patients (11).  
At the time of discovery, the contribution of PBX1-R184P towards disease causality was uncertain, 
and in vitro functional assessment was inconclusive. In order to elucidate the contribution of the 
PBX1 variant towards the phenotypes observed in our patient, we created a knock-in mouse model of 
the variant, PBX1-R184P, to functionally assess the impact of the variant during embryonic 
development. Homozygosity of the R184P variant was embryonic lethal, with embryos affected by 
multiple developmental anomalies including cardiac phenotypes similar to our patient. We also 
observed cardiac defects in a proportion of heterozygous embryos, indicating a dominant model of 
inheritance. Here, we describe the generation and comprehensive analysis of the first animal model of 
a PBX1 missense variant and provide functional evidence of the pathogenicity of the variant observed 
in our patient.       
Results 
Identification of a de novo missense PBX1 variant in a patient with CHD and extra-cardiac 
phenotypes 
The proband is the youngest of 6 children of healthy parents (Figure 1A). He has four healthy older 
brothers and one healthy older sister. He was born at a gestational age of 39 weeks. Echocardiography 
revealed that the proband had tetralogy of Fallot with absent pulmonary valve. There was a single 
large ventricular septal defect (VSD) with anterior and rightward deviation of the infundibular septum 
and the aorta overriding the interventricular septum. There was moderate pulmonary annular 
hypoplasia measuring 12 mm and the pulmonary valve was noted to be absent with severe stenosis 
and regurgitation (peak gradient of 99 mmHg, median gradient of 67 mmHg). The pulmonary arteries 
were dilated with the right artery at 1.7 cm and the left pulmonary artery at 1.2 cm. A small patent 
foramen ovale was observed during surgery. The right ventricle was mildly dilated and hypertrophied 
with reasonable systolic function. The proband underwent surgical correction three months after birth 
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with RV-PA conduit insertion, PA plication, VSD repair, and closure of PFO. Transthoracic echo one 
month after surgery revealed a small residual VSD with left-to-right blood flow, normal left 
ventricular systolic function, and hypertrophied right ventricle. Electrocardiogram did not reveal any 
conduction defects. 
Assessment at one year of age placed the proband in the 25th percentile of body weight, 90th percentile 
of length, and 50-90th percentile of head circumference. The proband was noted to suffer from 
recurrent bronchiolitis episodes during the first year of life. Renal ultrasound imaging of the proband 
revealed increased echogenicity of both kidneys. The proband was later diagnosed with autism, mild 
craniofacial (broad nasal tip, thick lips, prominent philtrum, anteverted ears) and skeletal phenotypes 
(clinodactyly) were also observed.  
Preliminary cytogenetic tests (MLPA and whole genome SNP microarray) did not detect 
chromosomal or copy number abnormalities. Whole exome sequencing was undertaken on the 
proband and the parents to potentially identify a monogenic cause of disease. No damaging variants in 
genes known to cause CHD were identified. All variants that segregated with disease were then 
considered (SI table 1). A novel de novo missense variant (c.551G>C p.R184P) was identified in the 
proband within the PBX1 gene, which encodes a homeodomain-containing transcription factor (16). 
To verify the de novo status of the variant, the proband, parents, and the four older brothers were 
Sanger sequenced (Figure 1B). The variant was not detected in the parents or the siblings.   
PBX1 contains three highly conserved regions; PBC-A, PBC-B, and the homeodomain (Figure 1C). 
The main functional domains of PBX1 are found in these conserved regions such as those motifs 
required for interaction with co-factors. R184P variant falls within the PBX1 dimerisation motif 
where a pathogenic stop-gain variant was identified for CAKUTHED (Figure 1C, Table 1 and SI 
table 2). PBX1:c. 551G>C, p.R184P is not present in healthy control individuals in the 
ExAC/gnomAD database. The arginine residue at position 184 is highly conserved in eukaryotes 
(Figure 1D) and the substitution to a proline residue is predicted to be highly damaging towards 
protein function by multiple in silico predictors (SI table 1).    
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Creation of a knock-in mouse model of the R184P variant 
Despite the novelty, the high conservation, and the in silico pathogenicity of the PBX1-R184P variant, 
we were unable to unequivocally assign pathogenicity as per the guidelines established by the 
American College of Medical Genetics and determine the variant as the cause of the phenotypes 
observed in our patient. Therefore, we pursued functional assessment of the variant to determine its 
role in disease causality. We engineered a mouse model with the R184P variant using the CRISPR-
Cas9 system. The exact variant was produced in the mouse as the PBX1 protein shares identity 
between human and mouse (SI figure 1). Heterozygous mice were intercrossed to produce the three 
possible genotypes: wild-type (+/+), heterozygous (+/R184P), and homozygous (R184P/R184P). 
Mendelian ratios of the embryos were analysed at 6 stages of embryonic (E) development: E11.5, 
E13.5, E14.5, E15.5, E17.5, and at birth (SI figure 2). The expected number of embryos for each 
genotype was observed at each embryonic stage except for at birth where there was a complete loss of 
the homozygous genotype and a significant loss of the heterozygous genotype. Analysis of embryonic 
death during development revealed that a proportion of homozygous embryos began to die from 
E15.5 (15%), with 8% found to be dead at E17.5 and none were born alive (Figure 2A). 
Heterozygous embryos began to die at E17.5 (3%) and 45% died at birth. 
Measurements revealed that from E14.5, the homozygous mutant embryos weighed significantly less 
than their wild-type counterparts (Figure 2B). The weights of the homozygous embryos remained 
lower than wild-type embryos at E15.5, as well as at E17.5 when their weights were also significantly 
lower than heterozygous embryos. We utilised micro-CT imaging as a non-invasive method of 
producing high resolution 3D images of the embryos. This method permits detailed scrutiny of the 
internal organs of the embryos and allowed detection of phenotypes that deviated from typical organ 
structures and organisation. Collection of high resolution data also permits quantitative volumetric 
analysis of organs and the entire embryo. We observed that at E13.5, the homozygous embryos were 
larger than heterozygous embryos, however, by E17.5 the homozygous embryos were smaller than 
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both wild-type and heterozygous embryos (Figure 2C, SI figure 3). The homozygous embryos also 
displayed hunched posture, subcutaneous oedema, open eyes, and umbilical hernia (Figure 2D). 
Phenotypic analysis of the R184P knock-in mouse model 
Analysis of the micro-CT data revealed that the homozygous embryos had multiple organ system 
defects (Figures 3, 4, 5, 6, and SI figures 4, 5, 6). Heterozygous embryos also exhibited defects; 
although to a lesser extent than homozygous embryos.  
As our proband has congenital heart disease, we first focused on heart development of the mutant 
mice. Persistent truncus arteriosus (PTA), where the aorta and the main pulmonary artery does not 
septate, and ventricular septal defects (VSD) where the septum between the right and left ventricles 
does not completely separate the two ventricles, were observed in the hearts of homozygous embryos 
at all developmental stages (Figure 3A, B, C). PTA was not identified in the hearts of heterozygous 
or wild-type embryos. However, VSDs were observed in the hearts of heterozygous embryos from 
E13.5 to E15.5 (Figure 3A, C). At E13.5, 75% of heterozygous embryos had VSDs, 31% of 
heterozygous embryos at E14.5, 12.5% heterozygous embryos had VSDs at E15.5, but none were 
observed in heterozygotes at E17.5. Heart defects were not observed in wild-type embryos at any 
stage. 
Severe defects were also observed during lung development. We noted that the lungs were 
consistently dysmorphic in homozygous embryos at all stages examined from E13.5 to E17.5 (Figure 
4A). Homozygous lungs had the typical number of lung lobes (four lobes on the right, one lobe on the 
left), however they were poorly separated and hypoplastic. In contrast, lungs of both heterozygous and 
wild-type embryos were indistinguishable. The quantification of this phenotype confirmed the visual 
inspection of the homozygous lungs. At E17.5 when the greatest difference in lung size was observed, 
lung volume of the R184P/R184P embryos (mean ± SD; 0.007 ± 0.001 mm3) remained consistently 
below the volumes of the heterozygous (0.019 ± 0.003 mm3) and wild-type embryos (0.020 ± 0.003 
mm3) (Figure 4B).   
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We also noted a range of other phenotypes in the R184P mutant embryos. Homozygous embryos 
displayed spleen agenesis (failed spleen development), a phenotype not observed in the heterozygous 
or wild-type embryos at any stage of development (SI figure 4). Physiological umbilical hernia, 
whereby the intestines herniate outwards from the body to form a bulge on the abdomen, was 
observed in embryos of all genotypes up to E15.5 (SI figure 5). At E17.5, umbilical hernia was not 
observed in wild-type embryos, but was present in all homozygous embryos (Figure 2D). 12.5% of 
heterozygous embryos also had umbilical hernia at E17.5. We observed that embryos of all genotypes 
had open eyes until E17.5 when heterozygous and wild-type embryos exhibited closed eyes, by which 
time the eye-lids had formed (Figure 2D, SI figure 6). However, at E17.5, the eyes of homozygous 
embryos remained open. We also observed that the homozygous embryos displayed defects in thymus 
development where the thymi were either ectopic or absent (SI figure 4). The homozygous embryos 
had abnormal development of the trachea and the larynx (Figure 6A, SI figure 6). In a majority of 
heterozygous (88%) and wild-type embryos (100%) the larynx was patent from the earliest stage of 
our observations (at E13.5), and in all analysed embryos by E17.5. In contrast, in the homozygous 
embryos, the larynx failed to open until E17.5. Furthermore, in both heterozygous and wild-type 
embryos, the trachea is atretic at all stages prior to E17.5, at which time the trachea opens to the 
larynx. However, in the homozygous embryos the trachea remained atretic at all stages analysed. 
Homozygous embryos also displayed palatal defects whereby the palatal shelves of the maxilla that 
fuse in heterozygous and wild-type embryos by E15.5, do not fuse in the homozygous 
embryos (Figure 6B, SI figure 6). At E13.5 all embryos displayed lack of fusion of the palatal 
shelves, whereas at E14.5, 87% of wild-type, 88% of heterozygous, and 100% of homozygous 
embryos exhibited lack of palate fusion. By E17.5, all wild-type and heterozygous embryos showed 
fusion of the palatal shelves, while palates of all homozygous embryos continued to display cleft 
palates.  
The urogenital system is consistently affected in CAKUTHED (Table 1, SI table 2). Therefore, we 
examined the urogenital system of the mutant embryos for defects. Analysis of the homozygous 
embryonic kidneys revealed that they were hypoplastic and failed to ascend within the body cavity 
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during embryonic development. Analysis of the reconstructed kidneys showed that the volume 
of kidneys of homozygous embryos (right kidney: 0.00072 ± 0.00032 mm3, left kidney: 0.00074 ± 
0.00033 mm3) remain consistently lower than their heterozygous (right kidney: 0.0019 ± 0.0010 mm3, 
left kidney: 0.0020 ± 0.0010 mm3) and wild-type (right kidney: 0.0021 ± 0.0014 mm3, left kidney: 
0.0021 ± 0.0013 mm3) counterparts during development (Figure 5A, C). We also measured the 
position of the kidneys within the body cavities of the embryos, and noted that in homozygous 
embryos (right kidney: 0.7864 ± 0.0138 mm, left kidney: 0.7955 ± 0.0153 mm) the kidneys remain 
mispositioned caudally within the body while the kidneys of the heterozygous (right kidney: 0.7494 ± 
0.0453 mm, left kidney: 0.7584 ± 0.0371 mm) and wild-type embryos ascend up the body cavity 
(right kidney: 0.7363 ± 0.0400 mm, left kidney: 0.7361 ± 0.0453 mm) (Figure 5B, C). In 
homozygous embryos, the adrenal glands did not develop while they were present in the heterozygous 
and wild-type embryos (Figure 5C). 
In terms of gonadal development, we observed that in homozygous embryos until E15.5, gonads 
could not be distinguished by sex where the shape of the gonads were neither ovarian nor testicular 
but an intermediate shape (Figure 5D). However, by E17.5, the testes could be identified 
morphologically although they appeared to be at an earlier developmental stage than E17.5, and 
their position within the body appeared ectopic. Similarly at this stage, the ovaries, although no longer 
morphologically similar to the testes, appeared to be at an intermediate stage of development, earlier 
than E17.5, as assessed by morphological examination. Gonadal development of heterozygous and 
wild-type embryos proceeded as typical per stage and sex. 
Molecular analysis of the R184P defect 
The observed spectrum of phenotypes of the R184P model is very similar to those previously reported 
in Pbx1 knockout (KO) model (17). In order to examine whether the R184P variant affects PBX1 
expression, we assessed protein levels and transcripts in whole embryos at E11.5. By Western blot, 
we observed that levels of PBX1-R184P protein, as both PBX1a and PBX1b isoforms, were 
decreased when compared to heterozygous or wild-type embryos (Figure 7A). This was confirmed by 
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quantification of band intensity where protein levels in homozygous embryos were reduced relative to 
heterozygous and wild-type embryos by 2.26-fold and 2.71-fold respectively (Figure 7B). There was 
no difference in PBX1 protein levels between heterozygous and wild-type embryos. We assessed 
Pbx1 transcript to identify whether the missense variant was affecting Pbx1 mRNA possibly leading 
to lower protein levels in the homozygous embryos. Analysis of transcript levels by qPCR showed 
that Pbx1 expression was upregulated in both homozygous (3.2-fold) and heterozygous embryos (2.4-
fold) (Figure 7C) relative to wild-type. There was no difference between transcript expression of 
homozygous and heterozygous embryos. We also assessed the expression of closely related Pbx 
genes, Pbx2 and Pbx3, as well as PBX1-interacting partner, Meis2, and genes regulated by PBX1 
during development of the heart (Pax3), lungs (Fgf10), skeleton (Sox9), and kidneys (Pdgfrb) (Figure 
7C). We observed up-regulation of Pbx2 transcript in R184P homozygous embryos, relative to wild-
type (3.8-fold) and heterozygous (3.1-fold) embryos. Expression of Fgf10, directly regulated by 
PBX1 during lung development (18), was down-regulated in heterozygous (3.2-fold) and homozygous 
(3.1-fold) embryos compared to wild-type embryos. Sox9, hypothesised to function in parallel with 
PBX1 during chondrogenesis (17), was up-regulated in both heterozygous (4.5-fold) and homozygous 
(6.8-fold) embryos relative to wild-type embryos. Pdgfrb expression is repressed by PBX1 during 
early stages of kidney development (19), and in the R184P homozygous embryos its expression was 
up-regulated relative to both wild-type (4.4-fold) and heterozygous (5.4-fold) embryos. In contrast, 
the expression levels of Pbx3, Meis2, and Pax3 were not altered between genotypes.  
Discussion 
Here we have presented the first in vivo functional evidence that a missense variant in PBX1 is able to 
cause congenital defects. We characterised the R184P model in a comprehensive temporal manner, 
following the phenotypes throughout development and were able to observe the progression of defects 
from early in development until later stages. 
One of the most startling findings was the observation that the R184P homozygous embryos displayed 
phenotypes nearly identical to the Pbx1 constitutive KO embryos (9, 16, 17, 20-22). Comprehensive 
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analysis of the constitutive Pbx1 KO, first reported by Selleri et al., examined the embryos at E14.5 
(17). The constitutive KO displays multi organ defects as summarised in Table 2. Analysis of the 
R184P embryos at the same developmental stage showed that the major organs were affected in a 
similar manner. For example, the heart defects reported in the constitutive KO were PTA and VSD (9, 
20), which were the same heart phenotypes that were present in the R184P model. Hypoplastic lungs, 
hypoplastic pelvic kidneys, absent adrenal glands and spleen, were all phenotypes shared by the 
R184P model and the constitutive KO (17, 19, 21-23).  
Molecular analysis of PBX1 protein in the R184P embryos revealed significant loss of the PBX1 
protein in the R184P homozygous embryos at E11.5. This finding suggests that R184P may be a loss-
of-function allele where protein levels have fallen below a critical functional threshold. It is possible 
that the substitution of an Arginine to a Proline, whose rigid, cyclic structure is predicted to introduce 
a turn and disrupt secondary structure of the protein, may also impact the tertiary structure of PBX1. 
Consequently, such misfolding may destabilise the mutant protein thus leading to lower protein levels 
as observed.  
We eliminated the possibility that the lower protein levels are due to decreased Pbx1 transcripts by 
assessing whole embryo mRNA by qPCR.  We discovered that levels of Pbx1 transcript were in fact 
up-regulated in both homozygous and heterozygous embryos. This finding suggests the possibility of 
a compensatory mechanism whereby the mutant embryos react to decreased PBX1 protein levels by 
up-regulating gene transcription. Our transcriptional analysis also revealed that PBX family member, 
Pbx2, is transcriptionally upregulated in the homozygous embryos. Similar to the up-regulation of 
Pbx1 transcript in the homozygous embryos, this observation suggests an attempt at rescue of the 
R184P phenotypes by Pbx2, but not Pbx3, whose expression was not altered in the mutants. This 
indicates that PBX1 and PBX2 may act cooperatively during development and may share the 
regulation of developmental processes. This is consistent with previous findings that used compound 
mutant embryos of the Pbx genes (Pbx1, Pbx2, Pbx3) to show that heart development is dependent on 
combined dosages of the PBX proteins (9).  
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Multiple examples of genetic compensation have been reported in species such as yeast, drosophila, 
zebrafish, and mice (reviewed in (24)). This mechanism that becomes activated in response to genetic 
variations, functions to ensure the genetic robustness of an organism by maintaining viability and 
fitness. In a majority of embryos heterozygous for the R184P variant, this mechanism appears to have 
succeeded and indeed PBX1 protein levels are similar to wild-type protein levels. However, in those 
heterozygous embryos with abnormal phenotypes, it is possible that PBX1 protein levels may not 
reach wild-type levels. Furthermore, as we have observed, the same mechanism fails to increase 
protein levels in the R184P homozygous embryos, suggesting that the mutant protein is actively 
degraded. The penetrance of phenotypes in these embryos indicates that loss of PBX1 functionality is 
not recovered and that PBX1-controlled functions cannot be mediated by other factors such as PBX2 
during development. However, constitutive Pbx1 KO embryos die at E17.5, whereas in the R184P 
model only 8% of homozygous embryos succumb at E17.5. It is possible that presence of some 
remaining PBX1 protein, despite the structural deviance, may moderate the severity that is described 
when both alleles of the Pbx1 gene are lost.    
This compensatory mechanism may underlie the normal development of the majority of heterozygous 
embryos in the R184P model. It is also likely to be the reason why developmental defects were not 
reported in any heterozygous embryos in the constitutive Pbx1 KO. Our findings also suggest that 
protein levels may not reach the required threshold during early development as we observe heart 
defects in 75% of heterozygous embryos. However, by E17.5 none of the heterozygous embryos 
display heart defects, suggesting that PBX1 protein levels have reached the crucial amount required 
for typical heart development.  However, subcutaneous oedema and umbilical hernia persist in a small 
proportion of heterozygous embryos (SI figure 5), indicating that compensation may not recover all 
PBX1 functions affected by the variant.   
It appears that this compensatory mechanism may not be conserved in humans or that it might not be 
able to overcome the presence of a LOF allele. It is possible that either the necessary gene-gene or 
gene-environmental interactions that regulate this mechanism in mice are not preserved in humans. 
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This is evident in patients with heterozygous LOF PBX1 mutations. The compensatory mechanism 
would otherwise upregulate protein to functional levels, meaning that heterozygous LOF variants 
would not lead to disease. But as has been noted, heterozygous LOF PBX1 variants cause disease and 
are not found in control populations (Table 1, SI table 2).  
The advantage of assessing a missense variant is that it allows us to elucidate possible mechanisms of 
disease causality. Where a LOF causes disease by absence of protein product, missense variants have 
the ability to disrupt protein folding, protein-protein interactions, and protein-DNA interactions.  Our 
variant is missense, in fact it is the only missense variant in the PBX dimerisation domain associated 
with an abnormal human phenotype. As PBX1 is not a transcription factor that can bind DNA as a 
monomer, the association of binding partners plays an essential role in its functionality (16, 25). The 
central PBX dimerisation domain facilitates its interactions with itself as well as other cofactors (26). 
It is possible that the R184P variant interferes with homodimerisation and/or heterodimerisation. 
However, if the process being disturbed is homodimerisation, only PBX1 functions would be affected 
and our model would be identical to the constitutive Pbx1 KO mouse. Aside from observing 
phenotypes in some heterozygous embryos, we also observed novel phenotypes in the homozygous 
embryos that have not been reported in the constitutive KO such as ocular defects, cleft palate, and 
tracheal defects (Table 2). We expect that it is likely heterodimerisation that is perturbed by the 
R184P variant. Previously, missense variants have permitted the identification of protein regions that 
are responsible for its tissue specific functions (12). As our patient is affected by CHD it is likely that 
a heart-specific interaction is being impaired by the variant. Other patients with pathogenic variants at 
p.M224, p.R234, and p.R235 also have congenital heart defects, suggesting that this region (p.R184 – 
p.R235) is required for protein-protein interactions essential for heart development (see Table 1, SI 
table 2) (11).  
The most likely candidate is MEIS2, which interacts with PBX1 and most intriguingly share 
overlapping knockout phenotypes with the R184P model. Meis2 knockout model displays such 
phenotypes as PTA, cleft palate, eye-lid defect, and absent pulmonary valves (27), which when 
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combined with TOF is an extremely rare phenotype (1/10,000 TOF cases (28)) as observed in our 
patient. Unlike its family member MEIS1, which interacts with PBX1 via the N-terminal PBC-A 
domain, the location of MEIS2 interaction with PBX1 is not yet firmly established. Interestingly, 
human patients have been reported with de novo missense variants and copy number variants 
encompassing MEIS2 who share certain common phenotypes; cleft palate, VSD, and hearing loss (29-
32). These phenotypes are also observed in human patients with pathogenic PBX1 mutations (see 
Table 1, SI table 2). Craniofacial anomalies and cardiac defects are also observed in our patient with 
the R184P variant. Our transcriptional analysis revealed that Meis2 is not PBX1 dependent. Thus, 
given the commonality of the phenotypes shared between the R184P model and Meis2 loss-of-
function model, as well as the similarity of phenotypes observed in human patients with PBX1 and 
MEIS2 mutations, we believe that it is likely that the interaction between PBX1 and MEIS2 is being 
perturbed by the R184P variant. We cannot discount that other interactions may also be perturbed, 
however, this would require the identification and functional assessment of tissue-specific PBX1 
binding partners.  
Interestingly, we did not observe changes in expression of the PBX1 cardiac target gene, Pax3, in the 
R184P model. As Pax3 is expressed in pre-migratory cardiac neural crest cells at E8.0 where it is 
under PBX1 regulation (20), it is possible that any change in Pax3 expression is masked by the 
generalized Pax3 expression levels observed in the whole embryo where other factors may regulate its 
expression. Perhaps, it is also possible that the PBX1-Pax3 regulation occurs in a very refined 
temporal manner and that at E11.5 where we assessed transcription, Pax3 is no longer under PBX1 
control. However, we observed expression changes in genes regulated by PBX1 in other organ 
systems.  PBX1 regulates the expression of Fgf10 in the lungs to direct surfactant production during 
development. Loss of Pbx1 in the lungs leads to reduced expression of Fgf10, reduced production of 
surfactants, and perinatal lethality associated with failure of alveolar expansion (18). In the R184P 
model, we observed down-regulation of Fgf10 in both heterozygous and homozygous embryos. We 
did not observe significant morphological changes in lungs of heterozygous embryos, indicating that 
lung development is not impaired in heterozygous embryos. However, we cannot dismiss that 
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production of surfactants by the lungs may be impaired in these embryos that may compromise lung 
function at a post-natal stage. We also assessed the expression of Sox9, which was hypothesised by 
Selleri et al. (17) to function in parallel with PBX1 during chondrogenesis to maintain a population of 
proliferating chondrocytes. Loss of Pbx1 led to loss of proliferating chondrocytes and multiple 
skeletal defects in the constitutive Pbx1 KO. The authors saw no overall impact on Sox9 expression 
from E13.5-E15.5 as assessed by in situ hybridisation. We were unable to assess skeletal defects in 
the R184P model due to technical limitations imposed by micro-CT analysis. However, given the 
similarity between the R184P model and the constitutive KO, and the observed clinodactyly in the 
PBX1-R184P patient, it is highly likely that skeletal development is affected in the R184P mutant 
embryos. Sox9 expression is up-regulated in both heterozygous and homozygous embryos of the 
R184P model at E11.5. This suggests that SOX9 and PBX1 share overlapping functions during 
chondrogenesis and SOX9 may compensate for the loss of PBX1 to a certain extent. Furthermore, we 
observed an up-regulation in expression of Pdgfrb in the kidneys of the homozygous embryos. 
Previous assessment of kidney development has shown that PBX1 is crucial for maintaining a 
population of vascular mural cell (VMC) progenitors by repressing the expression of Pdgfrb (19). The 
loss of Pbx1 led to premature up-regulation of Pdgfrb in the VMC progenitors leading to premature 
differentiation of the VMC population as well as disruption of renal vasculature development. The up-
regulation of Pdgfrb in the R184P homozygous embryos indicates that the VMC progenitors in these 
kidneys are becoming prematurely differentiated, and that this loss of progenitors may underlie the 
hypoplasticity of the kidneys that we observe in these embryos.    
The spectrum of phenotypes reported in the R184P and the constitutive KO models are becoming 
increasingly recapitulated in humans with PBX1 mutations (Table 1, SI table 2). Heart defects are 
reported in 5/16 patients who also have respiratory defects, and genitourinary defects are observed in 
16/16 patients. Craniofacial defects are seen in 13/16 patients, and developmental defects (physical 
and neurological) observed in 12/16 patients. Patients with previously unobserved phenotypes such as 
ectopic thymus, small spleen and small adrenal glands have been discovered (unpublished data, 
manuscript in preparation). These observations suggest that the full spectrum of Pbx1-related 
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phenotypes should be expected in human patients with mutations in PBX1 and that the pre-natal 
identification of a pathogenic PBX1 variant may allow prognostication that would permit early 
intervention of some phenotypes.   
What is also notable when comparing the two patient groups presented in Table 2 is the clear 
phenotypic variability prevalent between patients with pathogenic PBX1 variants. Interestingly, a 
patient has been reported with a loss-of-function variant at the exact amino acid position as the R184P 
patient, p.R184* (see Table 2, SI table 1) (14).This patient was reported within a small cohort of 
CAKUTHED patients and was diagnosed with renal defects, dysmorphic features, developmental 
delay, but no heart defects whereas the R184P has CHD associated with syndromic phenotypes. Aside 
from variable expressivity, incomplete penetrance of damaging variants has also been observed 
whereby a patient has been reported with a mutation in PBX1 at p.R288* with renal, craniofacial, 
cardiac, and auditory defects (see Table 2, SI table 1) (11). An individual with the same variant is 
reported in the gnomAD genome browser as a healthy reference individual without congenital defects. 
Although it is evident that there are several mutational hotspots within PBX1 that are susceptible to 
disease causing mutations, the penetrance of PBX1 variants and the expressivity of phenotypes appear 
to be highly variable and possibly dependent on multiple factors such as interacting partners and 
influence of genetic modifiers. 
Our findings show that the missense variant, R184P, leads to loss of protein that results in a near-
phenocopy of the Pbx1 constitutive KO mouse. However, the presence of novel phenotypes indicates 
a secondary mechanism of disease causality whereby the interaction with cofactors may be perturbed. 
This in vivo functional assessment of a disease-causal variant observed in a patient with CHD, asserts 
PBX1 missense variants as capable of causing syndromic CHD where complex, cyanotic CHD falls 
within the spectrum of PBX1-related phenotypes. With the evidence generated by our functional 
study, we are now able to update the ACMG classification of the R184P variant to pathogenic thus 
assigning significant clinical utility to the variant. 
Materials and Methods 
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Patient details- recruitment, consent 
Ethical approval for this study was obtained from the Sydney Children’s Hospital Network Human 
Research Ethics Committee (approval number HREC/16/SCHN/73). The patient and family were 
recruited at Princess Margaret Hospital for Children, Perth, Australia at presentation to a pre-
admission clinic prior to cardiac surgery. Heart defect in the proband was confirmed by 
echocardiography.  
Whole exome sequencing  
The generation and analysis of WES data for this family has been reported elsewhere (5, 11).  
Creation of the CRISPR knock-in and mouse study 
The PBX1-R184P knock-in mouse was created using the Mouse engineering Garvan/ABR (MEGA) 
service of Australian Bioresources (ABR) using CRISPR-Cas9 technology. The following CRISPR 
guide was used to engineer the variant: GCTGAACTTGCGGTGGATGATGCTCACCATC 
CGCTCGATCTCCTTCGGAGAGATGGGCCTGGTCCGGCTTTGCTCTGGAAGCAGGTTCATC
ACGTGGGTGGTGAATTCATTGCATGCCTGCAGTGGTAACACGGTAAACATGGGGTGAAC 
within exon 4 of the mouse Pbx1 gene. The guide was injected into C57BL/6J embryos using 
electroporation and one male founder mouse with the variant was produced. Primers: 
5' TGAGAAAGACAGAGAAAGCTCGT 3' and 5' ATCTCCTGCAACCATGGATT 3' were used to 
amplify the target region, and induction of the variant was confirmed by Sanger sequencing. (SI 
figure 1).  
Phenotypic analysis of the mouse line was performed following the guidelines, and the approval 
of Garvan Institute of Medical Research/St. Vincent's Animal Experimentation Ethics Committee 
(research approval 15/27, 18/27). Male and female mice heterozygous for the knock-in allele were 
used in timed-matings to produce wild-type, heterozygous, and homozygous embryos at ages E11.5, 
E13.5, E14.5, E15.5 and E17.5 when the mothers were sacrificed and embryos harvested.  
MicroCT  
Embryo preparation  
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Embryos were fixed in 4% PFA/1% Gluteraldehyde for 3 days at 4°C. Afterwards, the fixed embryos 
were incubated in hydrogel (4% acrylamide, 0.05% BIS, 4% PFA, 0.25% VA044, 0.05% Saponin) for 
3 days at 4°C. The embryos were then polymerised in hydrogel using the X-Clarity Polymerisation 
System (Logos Biosystems) (-90 kPa, 37°C, 3 hrs 10 mins). Hydrogel was then removed from the 
embryos which were incubated in lugol solution (Sigma Aldrich) for 5 days prior to microCT 
scanning.  
Scanning  
Skyscan1272 (Bruker) was used for embryo scanning. Embryos at all stages were scanned using the 
following settings: resolution 4904 x 3280, filter 0.5 µm aluminium, rotation 180 degrees, rotation 
step 0.3. Image pixel size varied between stages: E13.5: 2 µm, E14.5: 2.5-4 µm, E15.5: 2 µm, E17.5: 
4 µm. Scans were reconstructed using NRecon (v1.7.1.0) and optimised for post-alignment, 
smoothing, ring artefacts, and beam hardening.  
Analysis  
Reconstructed scans were visualised via CTvox (v3.3.0), CT Analyser (v1.17.7.2+), resized using 
DataViewer (v1.5.4.0). Quantification of the volumes of embryos and organs was performed using 
AMIRA software (v2019.1). 3D models of organs were created by selecting the organ of interest and 
using the watershed function to remove all regions outside the organ of interest. Organs that could not 
be watershed were selected manually from the scanned data and interpolated. Label analysis function 
was used to quantify body/organ volumes.  
Western blot analysis 
Proteins were extracted from wild-type, heterozygous, and homozygous whole embryos at E11.5 in 
RIPA buffer (150 mM NaCl, 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM 
Tris pH 8.0). 30 µg of protein was loaded on a 4-15% GTX Stain-Free acrylamide gels (Biorad) in 
denaturing conditions with SeeBlue Plus2 prestained protein ladder (Biorad). The Stain-Free gel was 
activated using Chemidoc Stain-Free gel activation protocol (Biorad). The proteins were transferred to 
a nicrocellulose membrane (0.45 µM pore size, Amersham). Transference of protein was confirmed 
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by imaging the membrane using the Stain-Free blot protocol of the Chemidoc. Rabbit-anti PBX1 
antibody (#4342, Cell Signalling Technologies) was used to detect PBX1 protein 
using WesternBreeze (Thermofisher Scientific) according to the manufacturer's instructions. 
Quantification of band intensity was performed using ImageJ. 
Quantitative real-time PCR 
E11.5 whole embryos were collected, snap frozen in liquid nitrogen and stored at -80°C. Total RNA 
was isolated using TriReagent (Life Technologies) following manufacturer's instructions. The tissues 
were homogenised using an insulin syringe. RNA purity (A260/A280 ratio ≥1.8) and concentration 
was measured using the NanoDrop ND-1000 Spectrophotometer. Total RNA 1 µg was converted into 
cDNA using QuantiTect Reverse Transcription kit according to manufacturer's instructions.  The 
qPCR reaction contained 4 ng of cDNA, LightCycler 480 SYBR Green 1 Master (Roche), forward 
and reverse primers (0.3 µM). All samples were run in triplicate on CFX384 (BioRad). The 
amplification protocol consisted of 3' 95°C for one cycle, 10'' 95°C 30'' 60°C for 39 cycles, and 
finished with a standard melting curve protocol. Melting curve analysis and quantification were 
performed using the CFX384 software (BioRad). Each primer used was validated to be specific for 
the gene by confirming a single peak on the melting curve. Raw values were exported to Microsoft 
Excel and analysed for absolute quantification using a standard curve. Primers used for qPCR: Pbx1 
For 5' GGGTGCAGGTTCAGACAACT 3’, Rev 5’ TGCATGCCTGCTCATACTTCT 3’; Pbx2 For 
5’ AGACATCGGGGACATTCTGC 3’, Rev 5’ TCCGAATGCTAAGGCCAGTT 3’; Pbx3 For 5’  
ATGTGCAGTCACAGGTGGAT 3’, Rev 5’ GCCAGCCTCCATTAGCGTTT 3’; Meis2 For 5’ 
GATCGCACAGGATGCGTTTC 3’, Rev 5’ GTCTAACCCATCGCCTCCAG 3’; Pax3 For 5’ 
CGCTTTTTCGTCTCGCCTTC 3’, Rev 5’ CAAGAGGGGTGGACACTTCC 3’; Fgf10 For 5’ 
AAGCCATCAACAGCAACTAT 3’, Rev 5’ ATTGTGCTGCCAGTTAAAAG 3’;  Sox9 For 5’  
AGTACCCGCATCTGCACAAC 3’, Rev 5’ TACTTGTAATCGGGGTGGTCT  3’; Pdgfrb For 5’ 
GTGGTCCTTACCGTCATCTCTC 3’, Rev 5’ GTGGAGTCGTAAGGCAACTGCA 3’; Hprt1 For 5' 
GCTTGCTGGTGAAAAG GACCTCTCGAAG 3’, Rev 5' CCCTGAAGTACTCATTATAGTCAAG 
GGCAT 3’. 
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Statistical analysis 
All statistical analyses were performed with Prism 7.03 (GraphPad Software). All datasets were tested 
for statistical significance using Student's t-test. Chi-squared test was used to analyse expected versus 
observed Mendelian ratios. In all figures, data represent mean ± standard deviation. 
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Figure 1. A novel de novo variant in PBX1 was identified in a patient with syndromic CHD by 
whole exome sequencing. (A) Pedigree of the family with the affected individual (black) carrying the 
de novo PBX1 variant PBX1:c.551G>C p.R184P. The patient presented with tetralogy of Fallot with 
absent pulmonary valve and later also diagnosed with bronchiolitis, autism, hyperechogenic kidneys, 
skeletal (clinodactyly) and craniofacial defects (broad nasal tip, thick lips, prominent philtrum, 
anteverted ears) (B) De novo presence of the variant was confirmed by Sanger sequencing. The older 
sister's DNA was not available for testing (NT). * represents the position of the nucleotide variation in 
the proband (c.551G>C) versus the reference allele in the parents (c.551G). (C) A schematic 
representation of the PBX1 protein indicating the functional domains; PREP1 dimerisation domain 
(green), PBX dimerisation domain (yellow), inhibitory helix (blue), homeodomain (pink), and 
cooperativity helices (purple). The positions of the pathogenic loss-of-function (red) and missense 
(orange) variants that are currently reported in the literature are presented. (D) Amino acid sequence 
alignment of reference and mutated human PBX1 protein (residues 181-195) with selected eukaryotes 
shows R184 is within a highly conserved region of the protein and that the arginine residue is 
completely conserved between species. 
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Figure 2. Functional assessment of the R184P knock-in mouse model. (A). Embryo survival was 
analysed at 6 stages during embryonic development, embryonic day (E) 11.5, E13.5, E14.5, E15.5, 
E17.5 and birth. Embryonic death was observed in both homozygous and heterozygous embryos. 
Death during development was not observed in wild-type littermates (n > 40 per stage). (B) 
Measurement of body weights of wild-type, heterozygous and homozygous embryos shows that 
homozygous embryos displayed lower body weight compared to wild-type and heterozygous embryos 
during development. (n ≥ 12 per stage; a, p < 0.01; b, p < 0.05; c, p < 0.01; d, p < 0.001). (C) Whole 
body volume quantification of embryos during development shows that homozygous embryos have 
lower body volumes during late development. (n ≥ 12 per stage; a, p < 0.05; b, p < 0.05; c, p < 0.05). 
(D) Whole embryo analysis by microCT shows the dysmorphic homozygous embryos at E17.5. Top 
panel: red arrow, umbilical hernia; yellow arrow, subcutaneous oedema. Bottom panel: red arrow, 
open eyes. Results are presented as mean ± SD. 
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Figure 3. Analysis of heart defects observed in the R184P knock-in mouse model. (A) Heart 
defects were observed in homozygous embryos throughout development and in a proportion of 
heterozygous embryos until E15.5. (n ≥ 14 per stage). (B) Homozygous embryos exhibited persistent 
truncus arteriosus (PTA) at all stages examined (E13.5- E17.5). (C) Ventricular septal defects (VSD) 
were observed in homozygous embryos examined at all stages. VSDs were also observed in a 
proportion of heterozygous embryos at E13.5, E14.5, and E15.5 (see panel A of this figure). AO, 
aorta; MPA, main pulmonary trunk; RVOT, right ventricular outflow tract; PTA, persistent truncus 
arteriosus; RV, right ventricle; LV, left ventricle; VSD, ventricular septal defect. Green arrows, 
typical heart morphology; red arrows, variation from the norm or presence of a defect.  
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Figure 4. Analysis of lung development in R184P knock-in mouse model. (A) Lungs in the 
homozygous embryos were smaller and dysmorphic compared to heterozygous and wild-type lungs at 
all analysed stages. (B) Quantification of the 3D reconstructions of the lungs showed a significant 
decrease in lung volume of the homozygous embryos at all stages. (n ≥ 12 per stage; a,b, p < 0.0001; 
c, p < 0.05; d, p <0.0001; e,f, p < 0.01; g,h, p < 0.0001). Results are presented as mean ± SD. 
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Figure 5. Analysis of urogenital phenotypes of the R184P knock-in mouse model. (A) 
Quantification of 3D reconstructions of the embryonic kidneys showed that both kidneys (right kidney 
and left kidney) of the homozygous embryos remained consistently smaller than the kidneys of the 
heterozygous and wild-type embryos at all stages examined. (Right kidney: n ≥ 12; a, p < 0.001; b, p 
< 0.0001; c, p < 0.05; d, p < 0.0001; e, p < 0.001; f, p < 0.01; g, p <0.001; h, p < 0.0001. Left kidney: 
n ≥ 12; a,b, p < 0.001; c, p < 0.01; d, p < 0.0001; e, p < 0.0001; f, p < 0.01; g,h, p < 0.0001). (B) 
Measurement of the position of the kidneys within the body cavity relative to crown-to-rump length 
(CRL). In homozygous embryos, the position of the kidneys remains unchanging between E13.5 and 
E17.5. In both heterozygous and wild-type embryos, the kidneys ascend within the body cavity. 
(Right kidney: n ≥ 13; a, p < 0.01; b, p < 0.01; c, p < 0.001. Left kidney: n ≥ 13; a, p < 0.001; b, p < 
0.05; c, p < 0.01; d, p < 0.001). (C) MicroCT analysis of the hypoplastic, pelvic kidneys of the 
homozygous embryos. Adrenal glands are absent in the homozygous embryos from the earliest stage 
examined at E13.5. (D) Gonads of homozygous R184P XY and XX embryos are dysmorphic and 
situated ectopically, presented at E14.5 and E17.5. Ad, Adrenal glands; Bl, Bladder; Ki, Kidneys; Li, 
Liver; Ov, Ovary; Ts, Testis. Green arrows, typical organ development. Red arrows, deviation from 
the norm or presence of defect. Red asterix, absence of adrenal gland. Results are presented as mean ± 
SD. 
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Figure 6. Defects in trachea, larynx, and palate were observed in R184P homozygous mice. (A) 
Larynges of the homozygous embryos fail to open during development. In wild-type and 
heterozygous embryos the larynx is open from E13.5. The trachea of the homozygous embryos 
remain atretic at all examined stages. The trachea of wild-type and heterozygous embryos are patent 
by E17.5. (n ≥ 14 per stage) (B) The secondary palate of the homozygous embryos does not fuse. 
Palatal defects are not observed in wild-type and heterozygous embryos (n ≥ 14 per stage). Data are 
presented at E14.5 and E17.5. Lr, Larynx; Tr, Trachea. Green arrows, typical organ development. Red 
arrows, deviation from the norm or presence of defect. 
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Figure 7. Assessment of PBX1 protein and mRNA expression in the R184P mouse model. (A) 
Western blot analysis of PBX1 protein expression in E11.5 embryos revealed that the protein is 
present at lower levels in the homozygous mutant embryos. (B) Quantification of PBX1 protein 
normalised to total protein loaded per lane. (n = 3 embryos per genotype, ** p < 0.01, **** p < 
0.0001). (C) Analysis of the Pbx1, Pbx2, Pbx3, Meis2, Pax3, Fgf10, Sox9, and Pdgfrb transcripts in 
E11.5 embryos relative to Hprt1 transcript levels. The expression of Pbx1 and Sox9 are up-regulated 
in heterozygous and homozygous embryos. Expression of Pbx2 and Pdgfrb are up-regulated in 
homozygous embryos. The expression of Fgf10 is down-regulated in heterozygous and homozygous 
embryos. The expression of Pbx3, Meis2 and Pax3 were not altered. (n= 3 embryos per genotype,* p 
< 0.05, ** p< 0.01). Results are presented as mean ± SD. 
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Table 1. Summary of reported patients with heterozygous, pathogenic, single gene, PBX1 mutations. 
 Missense 
  
LOF 
Publicatio
n 
 Slavotinek, 2017a Eoze
nou, 
2019b 
Riedham
mer, 
2017c 
Heidet, 2017d Slavotinek, 
2017a 
Le Tanno, 
2017e 
Heidet, 2017d 
PBX1 
amino 
acid 
position 
R18
4Pf 
M2
24K 
R2
27P 
R2
34P 
R23
5Q 
R23
5Q 
R235
Q 
G138Vfs
*40 
N143Tf
s*37 
R18
4* 
S262
Qfs*2 
R2
88* 
1.5
Mb 
dele
tion 
(onl
y 
PBX
1) 
0.27
6 
MB 
dele
tion 
(onl
y 
PBX
1) 
Delet
ion 
of 
one 
PBX
1 
allele 
Delet
ion 
of 
one 
PBX
1 
allele 
CHD Y Y   Y  Y             Y          
Renal/Uri
nary 
Y      Y Y     Y Y Y Y Y Y  Y Y Y 
Reproduc
tive 
  Y Y    Y Y Y Y     Y   Y  Y      
Skeletal Y            Y Y  Y     Y  Y Y     
Respirato
ry 
Y Y    Y Y             Y        
Digestive   Y   Y             Y Y         
Craniofac
ial 
 Y Y Y   Y     Y Y Y Y Y Y Y Y Y 
Nervous 
system  
  Y   Y   Y         Y   Y       
Growth/si
ze/body 
 Y Y Y Y       Y   Y Y Y Y Y    Y 
Otherg    Y Y   Y Y         Y Y         
Sex mal
e 
mal
e  
mal
e 
fem
ale 
mal
e 
mal
e 
male male female fema
le 
female fem
ale 
male male femal
e 
male 
The variant positions refer to PBX1 transcript NM_002585.4. Presence of a defect in the patient is indicated by 
Y. Patients are separated by those that harbour missense versus loss-of-function variants. (aSlavotinek et al., 2017 
(11), bEozenou et al., 2019 (12), cRiedhammer et al., 2017 (13), dHeidet et al., 2017 (14), eLe Tanno et al., 2017 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz231/5585438 by U
niversity of C
alifornia, San Francisco user on 13 N
ovem
ber 2019
36 
 
(15), fCurrent manuscript). gOther include phenotypes that do not fall within any other category. For more detail 
refer to SI table 2. 
 
 
Table 2. Phenotype comparison of the R184P and the original Pbx1 constitutive knock-out mouse models. 
  R184P model Pbx1 constitutive KOa  
  R184P/R184P +/R184P  -/- 
Cardiac VSD; PTA VSD VSD; PTA 
Haematopoietic  Aplastic spleen Not observed Aplastic spleen; anaemia 
Renal/Urinary Hypoplastic, underdifferentiated, 
pelvic kidneys 
Not observed Hypoplastic, underdifferentiated, 
ectopic kidneys 
Reproductive Delayed gonad differentiation, 
indifferent at E14.5, ectopic at E17.5 
Not observed Sex differentiation arrest; loss of 
müllerian duct in both sexes 
Skeletal Not observed Not observed Skeletal agenesis malformations 
Respiratory Atretic larynx (resolves by E17.5); 
Atretic trachea; hypoplastic lungs 
Not observed Hypoplastic lungs 
Digestive Narrow oesophagus; hypoplastic, 
ectopic stomach; hypoplastic liver 
Not observed Hypoplastic liver; hypoplastic 
stomach; hypoplastic gut 
Craniofacial Open eyelids at E17.5; unfused 
secondary palate (cleft palate) 
Not observed Mandibular hypoplasia; hypoplastic 
pinna 
Nervous system  Hypoplastic brain Not observed Not reported 
Endocrine Aplastic adrenal glands; hypoplastic, 
ectopic thymi 
Not observed Hypoplastic pancreas; aplastic 
adrenal glands; hypoplastic, ectopic, 
aplastic thymi; ectopic, aplastic 
parathyroid 
Embryo 
(growth/size) 
Umbilical hernia; subcutaneous 
oedema; hunched posture 
Umbilical hernia; 
subcutaneous 
oedema  
Subcutaneous oedema; hunched 
posture 
VSD, ventricular septal defect, PTA, persistent truncus arteriosus. (a amalgamated phenotypes from 
(17), (33), (34), (21, 35), (36), (22), (9), (20)). 
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Abbreviations 
ACMG American College of Medical Genetics, Ad Adrenal glands, AO Aorta, Bl Bladder, 
CAKUTHED Congenital anomalies of kidney and urinary tract syndrome with or without hearing 
loss, abnormal ears, or developmental delay, CHD Congenital heart disease, CRL Crown to rump 
length, Ki Kidneys, KO Knockout, Li Liver, LOF Loss of function, Lr Larynx, LV left ventricle, 
MPA Main pulmonary trunk,  Ov Ovary, PA Pulmonary artery, PBX Pre B-cell leukemia, PFO Patent 
foramen ovale, PTA Persistent truncus arteriosus, RV Right ventricle, RVOT right ventricular outflow 
tract, TALE Three amino acid loop extension, TOF Tetralogy of Fallot, Tr Trachea, Ts Testis, VMC 
Vascular mural cells, VSD Ventricular septal defect, WES Whole exome sequencing. 
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